FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1976942216> ?p ?o ?g. }

• W1976942216 endingPage "NA" @default.
• W1976942216 startingPage "NA" @default.
• W1976942216 abstract "Dear Editor, Curcumin is a yellow–orange pigment obtained from the plant Curcuma longa. The powdered rhizome of this plant, called turmeric, is a common ingredient in curry powders and has a long history of use in traditional Asian medicine for a wide variety of disorders. In the last decade a large number of reports have been published on the beneficial effects of curcumin, and it has repeatedly been claimed that this natural product is efficient and safe for the prevention and treatment of several diseases including cancer. It is not surprising, therefore, that curcumin is currently sold as a dietary supplement and that numerous clinical trials are ongoing or recruiting participants to evaluate curcumin activity. But there is accumulating evidence that curcumin may not be so effective and safe. Because such evidence is not generally acknowledged, the purpose of this letter is to briefly review the negative properties of curcumin so that they can be balanced against its beneficial effects. Most of the evidence that supports the therapeutic potential of curcumin is mainly based on in vitro studies in which curcumin was tested at concentrations in the micromolar range. Several reports have demonstrated, however, that the plasma concentrations of curcumin in people taking relatively high oral doses of this compound are very low, typically in the nanomolar range (reviewed in Ref. 4). For instance, a recent study examined the pharmacokinetics of a curcumin preparation in 12 healthy human volunteers 0.25–72 hr after an oral dose of 10 or 12 g. Using a high-performance liquid chromatography assay with a limit of detection of 50 ng mL , only 1 subject had detectable free curcumin at any of the time points assayed. The fact that curcumin also undergoes extensive metabolism in intestine and liver means that high concentrations of curcumin cannot be achieved and maintained in plasma and tissues after oral ingestion. This is a major obstacle for the clinical development of this agent and suggests that the therapeutic potential of oral curcumin is limited. The low clinical efficiency of curcumin in the treatment of several chronic diseases such as Alzheimer’s disease and cardiovascular diseases has been discussed recently. As far as cancer is concerned, in vitro studies have demonstrated that cancer cells do not die unless they are exposed to curcumin concentrations of 5–50 lM for several hours. Because of its poor bioavailability, these concentrations are not achieved outside the gastrointestinal tract when curcumin is taken orally. Because of its extensive metabolism in intestine and liver, these concentrations cannot be maintained for several hours in the gastrointestinal tract. This suggests that the chemotherapeutic potential of oral curcumin is limited even for the treatment of cancers of the gastrointestinal tract. Accordingly, when 15 patients with advanced colorectal cancer were treated with curcumin at daily doses of 3.6 g for up to 4 months, no partial responses to treatment or decreases in tumor markers were observed. A search of the website www.clinicaltrials.gov in July 2009 showed 34 clinical trials using curcumin in a wide variety of diseases, particularly in cancer. In some of these trials, patients with several types of cancer are receiving or will receive curcumin through the oral route. For instance, in an ongoing Phase II clinical trial (NCT00094445), participants with pancreatic cancer are receiving 8 g of curcumin by mouth every day for several 8-week-periods. As discussed before, the plasma concentrations of curcumin in people taking relatively high oral doses of curcumin are very low, typically in the nanomolar range. This means that the oral administration of curcumin does not lead to cytotoxic concentrations outside the gastrointestinal tract. If one assumes that tumor cell death is necessary to achieve an efficient therapeutic response, one should not expect a very positive outcome from this trial. A Phase II Trial is also recruiting participants to test if a daily oral dose of 8 g of curcumin can improve the efficacy of the standard chemotherapy gemcitabine in patients with locally advanced or metastatic adenocarcinoma of the pancreas (NCT00192842). The rationale for this trial is based on in vitro and in vivo data that suggest that noncytotoxic concentrations of curcumin may sensitize cancer cells to the effects of anticancer drugs such as gemcitabine. Although a daily dose of 1 g kg 1 of curcumin increased the antitumor effects of gemcitabine in an orthotopic model of pancreatic cancer, this dose of curcumin (e.g. 70 g in a 70-kg person) is almost 10 times higher than that used in the clinical trial testing the combination of curcumin and gemcitabine (8 g). This makes the outcome of this trial uncertain, as curcumin can either increase or reduce the efficiency of chemotherapy depending on the concentration at which it is used. Several strategies have been proposed to overcome the low oral bioavailability of curcumin. One of these strategies has entered clinical trials and consists of using the black pepper alkaloid piperine (bioperine) to increase the bioavailability of curcumin. This strategy, however, should be used cautiously, as piperine is a potent inhibitor of drug Le tt er s to th e E di to r" @default.
• W1976942216 created "2016-06-24" @default.
• W1976942216 creator A5006061477 @default.
• W1976942216 creator A5041517169 @default.
• W1976942216 creator A5051071578 @default.
• W1976942216 creator A5064386778 @default.
• W1976942216 creator A5088390075 @default.
• W1976942216 date "2010-01-01" @default.
• W1976942216 modified "2023-10-18" @default.
• W1976942216 title "The dark side of curcumin" @default.
• W1976942216 cites W1664719478 @default.
• W1976942216 cites W1965989247 @default.
• W1976942216 cites W1969815998 @default.
• W1976942216 cites W1971781743 @default.
• W1976942216 cites W1972179974 @default.
• W1976942216 cites W1973177531 @default.
• W1976942216 cites W1973993998 @default.
• W1976942216 cites W1976194786 @default.
• W1976942216 cites W1980008351 @default.
• W1976942216 cites W1984373476 @default.
• W1976942216 cites W1990991016 @default.
• W1976942216 cites W1992652784 @default.
• W1976942216 cites W2003392863 @default.
• W1976942216 cites W2004576295 @default.
• W1976942216 cites W2011993914 @default.
• W1976942216 cites W2018922462 @default.
• W1976942216 cites W2021711019 @default.
• W1976942216 cites W2028556682 @default.
• W1976942216 cites W2028700734 @default.
• W1976942216 cites W2028704769 @default.
• W1976942216 cites W2032533550 @default.
• W1976942216 cites W2033431239 @default.
• W1976942216 cites W2041669693 @default.
• W1976942216 cites W2052735421 @default.
• W1976942216 cites W2058461613 @default.
• W1976942216 cites W2064845643 @default.
• W1976942216 cites W2088926940 @default.
• W1976942216 cites W2092032160 @default.
• W1976942216 cites W2098259055 @default.
• W1976942216 cites W2099482827 @default.
• W1976942216 cites W2101745219 @default.
• W1976942216 cites W2109717482 @default.
• W1976942216 cites W2115494253 @default.
• W1976942216 cites W2115586774 @default.
• W1976942216 cites W2119300490 @default.
• W1976942216 cites W2121411068 @default.
• W1976942216 cites W2128822546 @default.
• W1976942216 cites W2133346842 @default.
• W1976942216 cites W2137631271 @default.
• W1976942216 cites W2138383523 @default.
• W1976942216 cites W2138508372 @default.
• W1976942216 cites W2138980596 @default.
• W1976942216 cites W2139221310 @default.
• W1976942216 cites W2139433964 @default.
• W1976942216 cites W2151101177 @default.
• W1976942216 cites W2158933426 @default.
• W1976942216 cites W2161431747 @default.
• W1976942216 cites W2164297850 @default.
• W1976942216 cites W2167225412 @default.
• W1976942216 doi "https://doi.org/10.1002/ijc.24967" @default.
• W1976942216 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19830693" @default.
• W1976942216 hasPublicationYear "2010" @default.
• W1976942216 type Work @default.
• W1976942216 sameAs 1976942216 @default.
• W1976942216 citedByCount "158" @default.
• W1976942216 countsByYear W19769422162012 @default.
• W1976942216 countsByYear W19769422162013 @default.
• W1976942216 countsByYear W19769422162014 @default.
• W1976942216 countsByYear W19769422162015 @default.
• W1976942216 countsByYear W19769422162016 @default.
• W1976942216 countsByYear W19769422162017 @default.
• W1976942216 countsByYear W19769422162018 @default.
• W1976942216 countsByYear W19769422162019 @default.
• W1976942216 countsByYear W19769422162020 @default.
• W1976942216 countsByYear W19769422162021 @default.
• W1976942216 countsByYear W19769422162022 @default.
• W1976942216 countsByYear W19769422162023 @default.
• W1976942216 crossrefType "journal-article" @default.
• W1976942216 hasAuthorship W1976942216A5006061477 @default.
• W1976942216 hasAuthorship W1976942216A5041517169 @default.
• W1976942216 hasAuthorship W1976942216A5051071578 @default.
• W1976942216 hasAuthorship W1976942216A5064386778 @default.
• W1976942216 hasAuthorship W1976942216A5088390075 @default.
• W1976942216 hasBestOaLocation W19769422161 @default.
• W1976942216 hasConcept C2778250585 @default.
• W1976942216 hasConcept C71924100 @default.
• W1976942216 hasConcept C98274493 @default.
• W1976942216 hasConceptScore W1976942216C2778250585 @default.
• W1976942216 hasConceptScore W1976942216C71924100 @default.
• W1976942216 hasConceptScore W1976942216C98274493 @default.
• W1976942216 hasLocation W19769422161 @default.
• W1976942216 hasLocation W19769422162 @default.
• W1976942216 hasOpenAccess W1976942216 @default.
• W1976942216 hasPrimaryLocation W19769422161 @default.
• W1976942216 hasRelatedWork W1506200166 @default.
• W1976942216 hasRelatedWork W2039318446 @default.
• W1976942216 hasRelatedWork W2080531066 @default.
• W1976942216 hasRelatedWork W2581018598 @default.

• next